Colleen Kusy
Stock Analyst at Baird
(1.00)
# 3,737
Out of 4,908 analysts
48
Total ratings
30.95%
Success rate
-14.4%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Colleen Kusy
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APLS Apellis Pharmaceuticals | Maintains: Outperform | $47 → $50 | $19.28 | +159.34% | 12 | Jul 18, 2025 | |
| NUVL Nuvalent | Maintains: Outperform | $105 → $112 | $82.46 | +35.82% | 2 | Jun 25, 2025 | |
| ELVN Enliven Therapeutics | Maintains: Outperform | $40 → $52 | $21.87 | +137.77% | 3 | Jun 16, 2025 | |
| AGEN Agenus | Maintains: Neutral | $4 → $6 | $6.09 | -1.48% | 4 | Jun 4, 2025 | |
| OCS Oculis Holding AG | Maintains: Outperform | $37 → $41 | $17.40 | +135.63% | 4 | Mar 13, 2025 | |
| CHRS Coherus Oncology | Maintains: Outperform | $4 → $6 | $0.89 | +576.59% | 5 | Dec 5, 2024 | |
| SYRE Spyre Therapeutics | Maintains: Outperform | $50 → $65 | $16.35 | +297.55% | 2 | Nov 13, 2024 | |
| MRSN Mersana Therapeutics | Maintains: Neutral | $4 → $3 | $0.36 | +734.96% | 4 | Aug 14, 2024 | |
| OCUL Ocular Therapeutix | Maintains: Outperform | $18 → $17 | $11.52 | +47.57% | 4 | Aug 8, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Outperform | $27 → $25 | $11.06 | +126.04% | 1 | Mar 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $255 → $210 | $4.02 | +5,123.88% | 1 | Aug 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $30 → $34 | $2.49 | +1,265.46% | 5 | Apr 7, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $230 | $2.70 | +8,418.52% | 1 | Nov 2, 2021 |
Apellis Pharmaceuticals
Jul 18, 2025
Maintains: Outperform
Price Target: $47 → $50
Current: $19.28
Upside: +159.34%
Nuvalent
Jun 25, 2025
Maintains: Outperform
Price Target: $105 → $112
Current: $82.46
Upside: +35.82%
Enliven Therapeutics
Jun 16, 2025
Maintains: Outperform
Price Target: $40 → $52
Current: $21.87
Upside: +137.77%
Agenus
Jun 4, 2025
Maintains: Neutral
Price Target: $4 → $6
Current: $6.09
Upside: -1.48%
Oculis Holding AG
Mar 13, 2025
Maintains: Outperform
Price Target: $37 → $41
Current: $17.40
Upside: +135.63%
Coherus Oncology
Dec 5, 2024
Maintains: Outperform
Price Target: $4 → $6
Current: $0.89
Upside: +576.59%
Spyre Therapeutics
Nov 13, 2024
Maintains: Outperform
Price Target: $50 → $65
Current: $16.35
Upside: +297.55%
Mersana Therapeutics
Aug 14, 2024
Maintains: Neutral
Price Target: $4 → $3
Current: $0.36
Upside: +734.96%
Ocular Therapeutix
Aug 8, 2024
Maintains: Outperform
Price Target: $18 → $17
Current: $11.52
Upside: +47.57%
ORIC Pharmaceuticals
Mar 12, 2024
Reiterates: Outperform
Price Target: $27 → $25
Current: $11.06
Upside: +126.04%
Aug 5, 2022
Maintains: Outperform
Price Target: $255 → $210
Current: $4.02
Upside: +5,123.88%
Apr 7, 2022
Maintains: Outperform
Price Target: $30 → $34
Current: $2.49
Upside: +1,265.46%
Nov 2, 2021
Initiates: Outperform
Price Target: $230
Current: $2.70
Upside: +8,418.52%